A Simple and Sensitive Fully Validated HPLC-UV Method for the Determination of 5-Fluorouracil and Its Metabolite 5,6-Dihydrofluorouracil in Plasma
- 1 February 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 27 (1) , 25-30
- https://doi.org/10.1097/00007691-200502000-00006
Abstract
The authors developed a simple and sensitive, fully validated HPLC-UV method for the determination of both 5-FU and its metabolite DHFU in small-volume plasma samples. The analytes were separated on a 4.6 × 250 mm ID Atlantis dC18 5-μm column with isocratic elution at room temperature. Chlorouracil was used as internal standard. The analytes were detected with an UV diode array detector. DHFU was detected at 205 nm, 5-FU at 266 nm, and chlorouracil at both wavelengths. The limits of quantification in plasma were 0.040 μg /mL for 5-FU and 0.075 μg/mL for DHFU. Linearity, accuracy, precision, recovery, dilution, freeze-thaw stability, and stability in the sample compartment were evaluated. The method appeared linear over a range from 0.04 to 15.90 μg/mL for 5-FU and from 0.075 to 3.84 μg/mL for DHFU. The method appeared very suitable for therapeutic drug monitoring and pharmacokinetic studies of 5-FU because of its simple extraction and small sample volume. Problems in earlier published methods with interfering peaks and variable retention times were overcome. The method appeared also to be suitable for detection of uracil and its metabolite dihydrouracil in plasma.Keywords
This publication has 22 references indexed in Scilit:
- Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer PatientsTherapeutic Drug Monitoring, 2002
- Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD geneBritish Journal of Cancer, 2002
- Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsAnnals of Oncology, 2001
- 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical DevelopmentInvestigational New Drugs, 2000
- Known variant DPYD alleles do not explain DPD deficiency in cancer patientsPharmacogenetics, 2000
- Therapeutic drug monitoring of antimetabolic cytotoxic drugsBritish Journal of Clinical Pharmacology, 1999
- Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?Clinical Pharmacokinetics, 1999
- Individualizing Therapy with 5-Fluorouracil Related to Dihydropyrimidine Dehydrogenase: Theory and LimitsTherapeutic Drug Monitoring, 1996
- 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancerBritish Journal of Cancer, 1989
- Fluorouracil: biochemistry and pharmacology.Journal of Clinical Oncology, 1988